Get the Stockscreener App
42.60
0.81%
-0.35
After Hours:
42.60
Qiagen Nv stock is traded at $42.60, with a volume of 2.45M.
It is down -0.81% in the last 24 hours and up +3.52% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$42.95
Open:
$42.43
24h Volume:
2.45M
Relative Volume:
0.92
Market Cap:
$8.80B
Revenue:
$2.10B
Net Income/Loss:
$402.17M
P/E Ratio:
22.01
EPS:
1.9357
Net Cash Flow:
$403.87M
1W Performance:
-2.85%
1M Performance:
+3.52%
6M Performance:
-12.63%
1Y Performance:
-13.68%
1-Day Range:
$42.43
$43.06
1-Week Range:
$42.14
$43.79
52-Week Range:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, NTRA, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
42.60 | 8.87B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
585.72 | 217.52B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.64 | 142.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
314.04 | 44.67B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
546.18 | 43.41B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.49 | 41.95B | 7.23B | 1.41B | 1.09B | 4.979 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen stock holds steady after Q2 2026 beat and guidance reaffirmation - AD HOC NEWS
Handelsbanken Fonder AB Takes $2.91 Million Position in Qiagen N.V. $QGEN - marketbeat.com
QIAGEN NV Revenue Breakdown – TRADEGATE:QIA - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen stock holds above $43 as Q2 2026 beat backs cautious valuation - ad-hoc-news.de
Qiagen (QGEN) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Qiagen stock holds above $43 as Q2 2026 earnings beat outlook - AD HOC NEWS
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip? - Yahoo Finance
Qiagen stock steadies after Q2 2026 guidance is reaffirmed - AD HOC NEWS
Qiagen stock gains after Q2 beat and fresh FDA clearance - AD HOC NEWS
Qiagen NV Annual Shareholders Meeting Transcript - GuruFocus
Qiagen N.V. : DZ Bank reiterates its Buy rating - marketscreener.com
Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing - The Globe and Mail
Qiagen N.V. (QGEN) Latest Stock News & Headlines - Yahoo! Finance Canada
Qiagen Sees Unusually High Options Volume (NYSE:QGEN) - marketbeat.com
Goldman Sachs lifts Qiagen voting rights to 2.63% via instruments - Bitget
Qiagen NV (QGEN) Shares Surge 3.7% -- What GF Score of 76 Tells Investors - GuruFocus
New QIAGEN Test Detects 20 Pathogen Targets in About an Hour - Stock Titan
QGEN Maintained by Citigroup -- Price Target Raised to $45.00 - GuruFocus
QIAGEN Wins FDA Clearance for a One-Hour Bloodstream Infection Test, With Montgomery County Ties Behind It - BioBuzz
Understanding Qiagen (QGEN) Reliance on International Revenue - Yahoo Finance
Qiagen N.V. (QGEN) Investor Outlook: Analyzing Growth Potential With An 8.24% Upside - directorstalkinterviews.com
Qiagen N.V. : Deutsche Bank remains its Buy rating - marketscreener.com
Qiagen NV (QGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
63,219 Shares in Qiagen N.V. $QGEN Bought by The Manufacturers Life Insurance Company - marketbeat.com
Qiagen Q2 Earnings Call Highlights - MarketBeat
QIAGEN Beats Q2 2026 Guidance, Reaffirms Full-Year Outlook Amid Mixed Demand - The Globe and Mail
William Blair Maintains Qiagen NV(QGEN.US) With Hold Rating - 富途牛牛
How Investors Are Reacting To Qiagen (QGEN) Capital Structure Overhaul And US$200 Million Repayment Plan - Sahm
Qiagen NV (QGEN) Stock News Today - TradingKey
Qiagen N.V. Stock 12‑Month Price Target Raised to $44.52, Implies 7% Upside - TradingView
QGEN Maintained by Barclays -- Price Target Raised to $40 - GuruFocus
Qiagen NV (QIA.SG) stock price, news, quote and history - Yahoo Finance UK
QGEN Maintained by JP Morgan -- Price Target Raised to $50 - GuruFocus
JPMorgan Chase & Co. Boosts Qiagen (NYSE:QGEN) Price Target to $50.00 - MarketBeat
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $45.5 to $46.09 - 富途牛牛
Qiagen NV | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Qiagen N.V. (QGEN) Stock Forecasts - Yahoo Finance
PTA-CMS: QIAGEN N.V.: Release of a capital market information - TradingView
Qiagen N.V. (NYSE: QGEN) Q2 2026 profit, $496.7M synthetic buyback and cash flows - stocktitan.net
QIAGEN N.V. (NYSE: QGEN) tops Q2 EPS outlook and reaffirms 2026 targets - Stock Titan
Qiagen N.V. (NYSE:QGEN) Given Average Rating of "Hold" by Analysts - marketbeat.com
Quantinno Capital Management LP Has $5.30 Million Stock Holdings in Qiagen N.V. $QGEN - marketbeat.com
Bank of America Corp DE Sells 418,992 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen NV (QGEN) (Q2 2026) Earnings Call Highlights: Beats Guida - GuruFocus
Qiagen (NYSE:QGEN) Updates Q3 2026 Earnings Guidance - MarketBeat
Qiagen N.V. : Jefferies reiterates its Buy rating - marketscreener.com
QIAGEN Q2 2026 slides: flat growth masks strong pillar performance - Investing.com
Qiagen: Q2 ahead of expectations; like peers, there's no change to guidance - marketscreener.com
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):